Clinical trial
Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on…
NCT00270348 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00270348 |
|---|---|
| Title | Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma |
| Official title | A Phase III, Multicenter, Double-Blind, Placebo Controlled, Non-Inferiority Study Assessing the Effects of Ciclesonide Metered Dose Inhaler 50 Mg/Day and 200 Mg/Day (Ex-Valve) Administered Once Daily on Growth in Children With Mild Persistent Asthma |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Takeda Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | ciclesonide |
| Enrollment | 450 |
| Start date | Dec 1, 2000 |
| Completion | Sep 1, 2004 |
| First posted | Dec 26, 2005 |
| Last update posted | Dec 28, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: